// Biotech and Pharma Therapeutics
How to Get Better Leadership Buy-In to Support Security and Privacy Efforts
November 12, 2025 / Healthcare Security / Leadership Buy-In / Cybersecurity Strategy / Telehealth Protection / Medical Device Security
Reframing cybersecurity as a strategic asset, not just a cost, can drive leadership buy-in—especially in healthcare, where security enables innovation, expands patient access, and protects clinical infrastructure from threats like ransomware and device vulnerabilities.
IBM and enGen Collaborate to Eliminate Errors in Member Enrollment
November 12, 2025 / AI Healthcare Enrollment / Member Data Integrity / Payer Efficiency / Healthtech Innovation / IBM enGen Collaboration
IBM and enGen launched an AI-powered enrollment platform to reduce costly health plan data errors, enhancing payer efficiency and improving member access to care by cutting processing time and minimizing downstream disruptions.
AES Cleanroom opens regional office in Research Triangle Park
November 12, 2025 / Modular Cleanroom Design / Life Sciences Manufacturing / Pharmaceutical Compliance / RTP Biotech Expansion / FDA Cleanroom Standards
AES Cleanroom Technology expands into Research Triangle Park to accelerate modular cleanroom delivery for life sciences, biotech, and pharmaceutical sectors—enhancing compliance, speed, and support in one of the nation’s top healthcare innovation hubs.
Medtronic names its next-gen renal denervation catheter as it builds the RDN market
November 6, 2025 / Renal Denervation Catheter / Hypertension Treatment Innovation / Transradial Access / Medtronic Symplicity Spyral+ / FDA RDN Approval
Medtronic’s new Symplicity Spyral+ catheter introduces a transradial approach to renal denervation, aiming to simplify hypertension procedures, improve patient recovery, and strengthen clinical outcomes with robust data, ahead of a projected 2026–2027 U.S. market launch.
Peru positions itself as a regional leader in good regulatory practices
November 12, 2025 / Pharmaceutical Regulation Peru / Good Regulatory Practices / Latin America Healthcare / Medicine Access Equity / Regulatory System Innovation
Peru is advancing good regulatory practices in pharmaceuticals, aiming to become a regional leader by enhancing system maturity, improving medicine access, and aligning with international standards, despite ongoing challenges in resources and technical infrastructure.
// 4th Industrial Revolution
Seeing What Others Can’t: The Power of Cybersecurity Dashboards in Modern Risk Management
November 12, 2025 / Healthcare Cybersecurity Dashboard / Digital Risk Management / Medical Data Protection / Vulnerability Scanning Healthcare / MDR Threat Response
Cybersecurity dashboards in healthcare act as digital X-rays, providing real-time visibility into vulnerabilities, automating threat responses, and integrating human risk metrics—enabling proactive protection of sensitive data, operational uptime, and patient safety in increasingly complex digital ecosystems.
How Sphaira plans to clear the roadblocks for its autonomous hospital transport tech
November 10, 2025 / Autonomous Patient Transport / Infection Control Technology / Hospital Robotics Integration / AI Medical Devices / Moby P1 Healthcare
Sphaira’s Moby P1 pod enables safe, autonomous hospital transport for immunocompromised and infectious patients, addressing staffing shortages and infection control with AI-driven navigation, filtration, and patient-family connectivity—already in use and expanding through partnerships like Mayo Clinic.
AI Company Matic Extends Automation to Medical Coding and Billing
November 12, 2025 / AI Medical Coding / Revenue Cycle Automation / Clinical Documentation AI / Healthcare Workflow Integration / Matic Codematic Platform
Matic expands its AI healthcare platform with Codematic, automating medical coding and revenue cycle management to bridge clinical documentation with operational workflows—enhancing coding accuracy, reimbursement, and efficiency through real-time, physician-informed intelligence.
AI’s model context protocol – everything you wanted to know but were afraid to ask
November 12, 2025 / AI Healthcare Integration / Model Context Protocol / Clinical Decision Support / FHIR for AI / Medical Workflow Automation
The Model Context Protocol (MCP) standardizes how AI systems securely connect with clinical knowledge sources, enabling safer, scalable integration of AI into healthcare workflows for accurate, auditable, and efficient decision-making in areas like prescribing and medication reconciliation.
SwRI-developed single-use 3D-printed bioreactor harvests induced Pluripotent Stem Cells
November 12, 2025 / iPSC Expansion Technology / 3D‑Printed Bioreactor / Regenerative Medicine / Neural Progenitor Cells / Automated Cell Culture
SwRI’s single‑use 3D‑printed bioreactor efficiently expands iPSCs at scale, supporting safer, automated production for regenerative therapies and enabling future differentiation into neural progenitor cells for potential spinal cord repair.
// Business & Markets
AbbVie to end Calico collab after 11-year run, plans layoffs: Stat
November 12, 2025 / AbbVie Calico Termination / ALS Drug Failure / Age-Related Disease R&D / Fosigotifator Clinical Trial / Genetic Medicine Strategy
AbbVie is ending its 11-year, $1.75B collaboration with Calico focused on age-related diseases after disappointing clinical results, including ALS candidate fosigotifator. The shift aligns with AbbVie’s pivot toward injectables and genetic medicine, with layoffs and future asset plans unclear.
Boston Scientific has a new tool to help TheraSphere fight cancer
November 12, 2025 / Y90 Liver Cancer Therapy / TheraSphere 360 Platform / Radioembolization Treatment / FDA Oncology Clearance / Boston Scientific Innovation
Boston Scientific’s newly FDA-cleared TheraSphere 360 Y-90 platform streamlines liver cancer treatment by enabling physicians to plan, dose, track, and manage yttrium-90 radioembolization therapy more efficiently through a browser-based, end-to-end digital system.
Ray Cohen sizes up the renal denervation market after $600M SoniVie sale
November 6, 2025 / Renal Denervation Market / SoniVie Ultrasound RDN / Hypertension Device Innovation / Boston Scientific Acquisition / Non-Contact Catheter Therapy
Following its $600M acquisition by Boston Scientific, SoniVie’s ultrasound-based renal denervation technology offers a non-contact, fast, and artery-sparing approach to treating hypertension—positioning it as a differentiated solution in the resurging RDN market post-FDA approvals.
House Rx Raises $55M to Scale In-Clinic Specialty Pharmacy Model
November 12, 2025 / Specialty Pharmacy Innovation / In-Clinic Medication Access / AI Pharmacy Management / PBM Alternative Model / Prior Authorization Automation
House Rx raised $55M to scale its AI-enabled, in-clinic specialty pharmacy model, which integrates pharmacists within care teams to improve medication access, reduce costs, and streamline prior authorizations—offering a patient-centered alternative to PBM-owned specialty pharmacies.
Altimmune Poised for $1B+ Opportunity as MASH Drug Aces Phase IIb
November 12, 2025 / MASH Drug Development / Pemvidutide Phase IIb / GLP1 Glucagon Agonist
Liver Fibrosis / Altimmune Clinical Success
Altimmune’s pemvidutide showed strong Phase IIb efficacy in MASH, improving disease resolution, fibrosis, and non‑invasive liver measures with excellent tolerability—positioning the dual GLP‑1/glucagon agonist as a potential best‑in‑class therapy entering late‑stage development.
// Legal & Regulatory
FDA unveils new regulatory roadmap for bespoke drug therapies
November 12, 2025 / FDA Bespoke Therapies / Rare Disease Treatment / Gene Editing Approval / Plausible Mechanism Pathway / Accelerated Drug Regulation
The FDA’s new “plausible mechanism” pathway accelerates bespoke therapies for ultra-rare or life-threatening conditions by allowing approval based on mechanistic targeting, preclinical validation, and real-world outcomes—reducing regulatory burdens for gene, RNA, or small molecule treatments.
Judge denies FTC’s bid to block $627M Surmodics buyout
November 12, 2025 / Surmodics GTCR Acquisition / Hydrophilic Coatings Market / Medical Device M&A / FTC Antitrust Ruling / Medtech Consolidation Update
A judge denied the FTC’s attempt to block GTCR’s $627M acquisition of Surmodics, clearing a key hurdle for the deal despite antitrust concerns over hydrophilic coating market concentration in medical devices.
Lyell boosts pipeline with acquisition of novel CAR T therapy
November 12, 2025 / CAR T Solid Tumors / Metastatic Colorectal Cancer / Lyell Immunopharma Pipeline / GCC Targeted Therapy / Cell Therapy Acquisition
Lyell Immunopharma acquired global rights to LYL273, a GCC-targeted CAR T therapy showing promising Phase I efficacy in metastatic colorectal cancer, aiming to enhance solid tumor response through controlled cytokine release and improved immune cell infiltration.
Stereotaxis nets FDA clearance for redesigned surgical robot
November 12, 2025 / Stereotaxis GenesisX Clearance / Robotic Surgery Innovation / Endovascular Navigation System / FDA Surgical Robotics / Hospital Infrastructure Solution
Stereotaxis received FDA clearance for GenesisX, a redesigned surgical robot for endovascular procedures with built-in magnetic shielding and simplified installation—removing key infrastructure barriers to adoption in hospitals.
March Biosciences wins FDA RMAT designation for MB-105
November 12, 2025 /CD5 CAR-T Therapy / T-Cell Lymphoma Treatment / RMAT Designation FDA / March Biosciences MB-105 / Cell Therapy Innovation
March Biosciences’ CD5-targeted CAR-T therapy, MB-105, received FDA RMAT designation for relapsed/refractory CD5-positive T-cell lymphoma, recognizing promising Phase II safety and efficacy data in a high-need patient population.
// Research & Development
New fiber-optic device could revolutionize deep brain stimulation
November 7, 2025 / Deep Brain Stimulation / Optogenetics Fiber Device / Neural Interface Innovation / PRIME Brain Technology / Multi-Site Optical Stimulation
Washington University researchers developed PRIME, a fiber-optic device enabling multi-site deep brain stimulation via optogenetics. The hair-thin implant delivers light to thousands of neural targets, potentially transforming neuroscience research and future brain-computer interfaces.
Telesurgery software provider Sovato lands Intuitive as a new investor in $26M Series B round
November 6, 2025 / Telesurgery Platform Investment / Remote Robotic Surgery / Sovato Intuitive Funding / Surgical Access Innovation / System-Agnostic Surgery Tech
Sovato Health raised $26M in Series B funding, including investment from Intuitive Surgical, to advance its system-agnostic telesurgery platform, enabling safe, remote operation of robotic surgical systems and addressing global surgical access and provider shortages.
Breakthroughs in theranostic nanomaterials for traumatic brain injury management
November 12, 2025 / Theranostic Nanomaterials TBI / Targeted Brain Drug Delivery / Real-Time Brain Monitoring / Neuroprotective Nanoparticles / Traumatic Brain Injury Innovation
Theranostic nanomaterials offer a dual-function approach to traumatic brain injury (TBI), enabling real-time diagnosis and targeted drug delivery. These engineered nanoparticles enhance neuroprotection, reduce inflammation, and support personalized, minimally invasive treatment strategies in TBI management.
Hidden household toxin triples liver disease risk, study finds
November 12, 2025 / PCE Liver Disease Risk / Environmental Toxin Exposure / Household Chemical Hazard / Tetrachloroethylene Health Effects / Liver Fibrosis Study
A new study links tetrachloroethylene (PCE), a common dry cleaning and household solvent, to a threefold increase in severe liver disease risk—even in individuals without obesity or alcohol-related factors—highlighting a hidden environmental health concern.
New study finds Ozempic and Mounjaro protect the heart too
November 12, 2025 / GLP1 Cardiovascular Benefits / Ozempic Heart Protection / Mounjaro Stroke Reduction / Type 2 Diabetes Therapy / Real-World Diabetes Study
A new study shows GLP-1 drugs semaglutide (Ozempic) and tirzepatide (Mounjaro) reduce major cardiovascular events by up to 18% in type 2 diabetes patients, offering heart protection beyond weight loss benefits.
// Politics
A MAHA Summit, minus the radical transparency
November 12, 2025 / MAHA Health Summit / Federal Health Policy / JD Vance Healthcare / Closed-Door Health Meetings / U.S. Health Leadership
Top U.S. health officials and Vice President JD Vance are attending a closed-door Make America Healthy Again (MAHA) summit in Washington, raising concerns over transparency in discussions likely to shape national healthcare policy.
US tariff and pricing reforms drive pharma localization and spur outsourcing-led investment shifts
November 12, 2025 / Pharma Manufacturing Localization / Drug Import Tariffs / U.S. Pricing Reform / Outsourcing Investment Strategy / Supply Chain Resilience
U.S. tariff and pricing reforms are prompting pharma companies to localize manufacturing, reduce import reliance, and pursue outsourcing-led investments, as seen in Pfizer’s and Roche’s recent acquisitions tied to supply chain resilience and domestic production incentives.
What Kennedy’s saturated fat guidelines would mean for American health
November 12, 2025 / Saturated Fat Guidelines / U.S. Dietary Policy / Cardiovascular Health Risk / Nutrition Science Debate / RFK Jr. Health Proposal
Health Secretary Robert F. Kennedy Jr.’s proposal to promote saturated fat in U.S. dietary guidelines has sparked concern among nutrition scientists, who warn it contradicts decades of evidence linking high saturated fat intake to cardiovascular disease.
Democratic House bill seeks repeal of WISeR prior authorization rules
November 11, 2025 / WISeR Prior Authorization / AI Medicare Oversight / Seniors Deserve SMARTER Care / CMS Healthcare Reform / Medical Decision-Making AI
Democratic lawmakers introduced a bill to repeal CMS’s AI-driven WISeR model, citing concerns that automated Medicare prior authorizations could delay or deny medically necessary care, increase administrative burdens, and endanger seniors’ health by prioritizing cost-cutting over clinical judgment.
Trump Announces Big Pharma Discounts of Weight Loss Drugs Ozempic and Zepbound
November 6, 2025 / Ozempic Zepbound Discounts / GLP1 Drug Pricing / Trump Weight Loss Announcement / Eli Lilly Novartis Deal / Diabetes Obesity Medication
President Trump announced major discounts on GLP-1 drugs Ozempic and Zepbound (also branded as Wegovy and Mounjaro), with Eli Lilly and Novartis agreeing to lower prices for weight loss and diabetes treatments amid rising demand and political focus.